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Abstract  
Acinetobacter ursingii is an aerobic, gram-negative, opportunistic microorganism which is rarely isolated among Acinetobacter species. We present 
two immunocompetent infants who developed bacteremia due to A.ursingii. The first patient is a two -month- old boy who had been hospitalized in 
pediatric surgery unit for suspected tracheo-esophageal fistula because of recurrent aspiration pneumonia unresponsive to antibiotic therapy. The 
second patient is a fourteen -month- old boy with prolonged vomiting and diarrhea. A. ursingii was isolated from their blood cultures. They were 
successfully treated with ampicillin-sulbactam. Although A.ursingii has recently been isolated from a clinical specimen; reports of infection with 
A.ursingii in children are rare. A.ursingii should be kept in mind as an opportunistic microorganism in children. 
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Introduction 
 
Acinetobacter species are the most common causative agents of 
health care associated infections such as meningitis, ventilator-
associated pneumonia, endocarditis and catheter-related bacteremia 
[1, 2]. Despite their low virulence, they have increasingly been 
recognized as opportunistic microorganisms particularly in 
hospitalized and immunocompromised patients. Acinetobacter 
species can be found widely in nature. The organism can be a part 
of the flora of the skin, the oral cavity and the upper respiratory, 
genital and gastrointestinal tracts. The skin may become a reservoir 
for Acinetobacter in hospitalized patients and health care provider 
[3]. Patients who have undergone a tracheostomy are at particularly 
high risk for colonization by Acinetobacter. Because they survive on 
inanimate surfaces for a long-term, these microorganisms can be 
commonly found in the hospital environment, particularly in moist 
areas such as in humidifiers and ventilators. Colonized medical 
equipment such as respiratory equipment and intravenous catheters 
may be responsible from nosocomial outbreaks [4]. Although A. 
ursingii, has recently been isolated from a clinical specimen, reports 
of infection with A. ursingii in children are rare [5]. Herein we report 
two cases with bacteremia due to A.ursingii in immunocompetent 
infants who were successfully treated. 
  
  




A two-month-old boy had been hospitalized in pediatric surgery unit 
for suspected tracheo-osefageal fistula. He was referred from 
another hospital with the diagnosis of recurrent aspiration 
pneumonia unresponsive to antibiotic therapy. On the admission, he 
had tachypnea and subfebrile fever on physical examination. 
Laboratory tests showed a white blood cell (WBC) of 10900/µl, C-
reactive protein (CRP) of 11.8 mg/L and normal biochemistry 
values. Peripheral blood culture was obtained. Twelve hours later, 
the BacT/Alert device (bioMerièux, Marseille, France) gave a signal 
indicating a growth of microorganism. Gram staining was positive 
for gram-negative coccobacilli. The microorganism was nonmotile, 
strictly aerobic, catalase-positive and oxidase-negative. Empirical 
antibiotic treatment with meropenem and amikacin was started. The 
next day, Vitek MS (bioMerièux, Marseille, France) identified the 
microorganism as Acinetobacter ursingii and reliability was 99.9%. 
The E-test used to describe antimicrobiological susceptibility showed 
that the microorganism was susceptible to ampicillin-sulbactam, 
gentamicin, ciprofloxacin and imipenem. The antibiotic therapy was 
de-escalated to ampicillin-sulbactam. On the third day of the 
treatment, control peripheral blood culture was taken and remained 




A fourteen-month-old boy with the diagnosis of gastroesophageal 
reflux disease was admitted to our hospital with complaints of 
vomiting and diarrhea for a month. On admission, his physical 
examination revealed fever (38.4°C). Because of the prolonged 
diarrhea and vomiting, patient was hospitalized and further 
investigated. Laboratory tests showed a WBC of 5800/µl, CRP of 3.2 
mg/L and normal biochemistry values. Peripheral blood culture was 
obtained and signaled growth for gram-negative bacilli. Empirical 
antibiotic treatment with meropenem and amikacin was started. 
Microorganism was identified as Acinetobacter ursingii by Vitek MS 
(bioMerièux) with a reliability of 99.9%. The e-test showed that A. 
ursingii was susceptible to ampicilin-sulbactam, gentamicin, 
ciprofloxacin and imipenem. The antibiotic therapy was deescalated 
to ampicin-sulbactam. On the third day of the treatment, control 
peripheral blood culture remained sterile. He was successfully 





Acinetobacter ursingii can cause life-threatening bloodstream 
infection especially in immunocompromised patients, but their 
correct identification is problematic. Currently, more than 32 
genomic species have been identified by molecular methods [6,7]. 
Virulence, epidemiology, antimicrobial susceptibility, clinical 
significance of Acinetobacter species may vary. Therefore, 
determining the prevalence of the Acinetobacter species causing 
invasive infection may be helpful in the management of infection 
[8,9]. Risk factors for infection with A.ursingii emerged as noso-
comial pathogens during the last 3 decades including underlying 
serious disease such as cancer, intravascular catheterization, 
treatment with broad spectrum antibiotics, prolonged 
hospitalization. Due to their ability for long-term survival in the 
environment, A.ursingii may spread among patients and cause 
nosocomial infections and outbreaks. Although A.ursingii have low 
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pathogenic potential, it has increasingly been described as 
opportunistic pathogen particularly in immunosupressed and 
patients in intensive care units [10]. Acinetobacter may cause 
suppurative infection such as peritonitis, endocarditis, osteomyelitis, 
arthritis, pancreatic and liver abcesses. Clinical manifestations are 
similar to other bacterial infections and may vary depending on the 
serious underlying disease and immune status. A.ursingii related 
bloodstream infection may occur as primary or secondary to 
respiratory or urinary tract and wound infection. Immunosupressed 
neonates are at particularly high risk for primary bacteremia, and 
clinical signs may vary ranging from an asymptomatic to septic 
shock and disseminated intravascular coagulation. Because of 
increasing antibiotic resistance, treatment of infections due 
to Acinetobacter spp. has become difficult. Antibiotic treatment 
should be determined by in vitro susceptibility testing. A. 
ursingii seems to be more susceptible to antimicrobial agents 
compared to A.baumannii. Infections due to A.ursingii are rare in 
healthy children. There are a few reports of infection with 
A.ursingii in the literature; most of the cases are 
immunocompromised with underlying serious disease. Report of a 
bacteremia caused by A.ursingii in an adult patient with oro-





Although A. ursingii, has recently been isolated from a clinical 
specimen, reports of infection with A. ursingii in children are rare. 
Our patients had neither of central venous catheter, immuno-
compromised status, severe underlying co-morbidities and 
prolonged hospitalization. Source of A.ursingii may either be the 
hospital or colonization prior to admission. As a conclusion, although 
rare, A.ursingii should be kept in mind as an opportunistic 
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